TTrialPathMatch Me to Trials
← Back to trials
RecruitingAnatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8

A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This phase II trial evaluates whether a multi-antigen vaccine called STEMVAC improves disease-free survival after surgery in patients with triple-negative breast cancer (TNBC) and moderate or extensive residual cancer burden. TNBC has an aggressive clinical course and poorer disease-free survival compared to other subtypes. While patients who have no remaining tumor in the breast or lymph nodes after surgery have excellent long-term outcomes, patients with moderate or extensive residual cancer burden remain at high risk for early disease return and poorer prognosis. STEMVAC is designed to target proteins that tumor cells use when they become more aggressive and start to spread, and it is believed to work by boosting the immune system to recognize and destroy the invader tumor cells that are causing the disease. Giving STEMVAC after surgery may improve disease-free survival rates in TNBC patients with moderate or extensive residual cancer burden.

Sponsor: University of Washington

You may qualify if…

  • ✓ At least 18 years of age
  • ✓ Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2
  • ✓ Triple-negative breast cancer as determined by the treating oncologist
  • ✓ Completed standard of care neoadjuvant chemotherapy in the opinion of their treating oncologist
  • ✓ Patients whose tumors progress on neoadjuvant therapy may be enrolled
  • ✓ No clinical evidence of local or distant recurrence
  • ✓ Plan to receive standard of care adjuvant directed therapy
  • ✓ Completed standard of care locoregional treatment, including definitive breast and lymph node surgery followed by standard radiation therapy, if recommended

You may not qualify if…

  • ✕ Toxicities related to prior exposure to immune checkpoint inhibitors for which immune checkpoint inhibitors cannot be safely continued as determined by study investigator
  • ✕ Germline BRCA1 or BRCA2 mutations with adjuvant olaparib planned within the study period
  • ✕ NOTE: If olaparib is not planned, then these patients are eligible
  • ✕ Any known cardiac conditions:
  • ✕ Symptomatic restrictive cardiomyopathy
  • ✕ Dilated cardiomyopathy
  • ✕ Unstable angina within 4 months prior to enrollment
  • ✕ New York Heart Association functional class III-IV heart failure on active treatment

Where it's recruiting

Washington

Seattle

Source: ClinicalTrials.gov · NCT07721259 · last updated 2026-11-19

A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Neg · TrialPath